Milestone Scientific (MLSS) Competitors

Milestone Scientific logo
$0.28 -0.02 (-5.78%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.29 +0.01 (+3.61%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MLSS vs. KEQU, OM, NRXS, HYPR, and MBOT

Should you buy Milestone Scientific stock or one of its competitors? Milestone Scientific's main competitors and comparable companies include Kewaunee Scientific (KEQU), Outset Medical (OM), NeurAxis (NRXS), Hyperfine (HYPR), and Microbot Medical (MBOT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Milestone Scientific compare to Kewaunee Scientific?

Milestone Scientific (NYSE:MLSS) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Kewaunee Scientific has higher revenue and earnings than Milestone Scientific. Milestone Scientific is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Scientific$9.42M2.67-$6.93M-$0.04N/A
Kewaunee Scientific$282M0.35$9.62M$2.7612.32

Milestone Scientific has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Kewaunee Scientific has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Milestone Scientific presently has a consensus price target of $1.00, suggesting a potential upside of 261.01%. Given Milestone Scientific's stronger consensus rating and higher probable upside, research analysts clearly believe Milestone Scientific is more favorable than Kewaunee Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Scientific
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kewaunee Scientific
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are held by institutional investors. 9.2% of Milestone Scientific shares are held by insiders. Comparatively, 14.1% of Kewaunee Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kewaunee Scientific has a net margin of 2.97% compared to Milestone Scientific's net margin of -52.01%. Kewaunee Scientific's return on equity of 11.61% beat Milestone Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone Scientific-52.01% -60.26% -40.23%
Kewaunee Scientific 2.97%11.61%4.82%

In the previous week, Milestone Scientific had 7 more articles in the media than Kewaunee Scientific. MarketBeat recorded 8 mentions for Milestone Scientific and 1 mentions for Kewaunee Scientific. Kewaunee Scientific's average media sentiment score of 0.89 beat Milestone Scientific's score of 0.38 indicating that Kewaunee Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Milestone Scientific
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kewaunee Scientific
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Kewaunee Scientific beats Milestone Scientific on 10 of the 16 factors compared between the two stocks.

How does Milestone Scientific compare to Outset Medical?

Milestone Scientific (NYSE:MLSS) and Outset Medical (NASDAQ:OM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Milestone Scientific has higher earnings, but lower revenue than Outset Medical. Milestone Scientific is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Scientific$9.42M2.67-$6.93M-$0.04N/A
Outset Medical$119.48M0.50-$81.65M-$3.87N/A

Milestone Scientific currently has a consensus price target of $1.00, indicating a potential upside of 261.01%. Outset Medical has a consensus price target of $10.00, indicating a potential upside of 216.46%. Given Milestone Scientific's stronger consensus rating and higher possible upside, equities research analysts plainly believe Milestone Scientific is more favorable than Outset Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Scientific
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Outset Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

5.8% of Milestone Scientific shares are held by institutional investors. 9.2% of Milestone Scientific shares are held by company insiders. Comparatively, 2.5% of Outset Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Milestone Scientific has a net margin of -52.01% compared to Outset Medical's net margin of -58.33%. Milestone Scientific's return on equity of -60.26% beat Outset Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone Scientific-52.01% -60.26% -40.23%
Outset Medical -58.33%-66.98%-28.40%

Milestone Scientific has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

In the previous week, Milestone Scientific had 1 more articles in the media than Outset Medical. MarketBeat recorded 8 mentions for Milestone Scientific and 7 mentions for Outset Medical. Outset Medical's average media sentiment score of 0.90 beat Milestone Scientific's score of 0.38 indicating that Outset Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Milestone Scientific
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Outset Medical
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Milestone Scientific beats Outset Medical on 10 of the 16 factors compared between the two stocks.

How does Milestone Scientific compare to NeurAxis?

Milestone Scientific (NYSE:MLSS) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Milestone Scientific has higher revenue and earnings than NeurAxis. Milestone Scientific is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Scientific$9.42M2.67-$6.93M-$0.04N/A
NeurAxis$6.53M7.52-$14.63M-$1.06N/A

Milestone Scientific currently has a consensus price target of $1.00, indicating a potential upside of 261.01%. NeurAxis has a consensus price target of $13.00, indicating a potential upside of 182.00%. Given Milestone Scientific's stronger consensus rating and higher possible upside, research analysts clearly believe Milestone Scientific is more favorable than NeurAxis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Scientific
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NeurAxis
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Milestone Scientific has a net margin of -52.01% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Milestone Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone Scientific-52.01% -60.26% -40.23%
NeurAxis -492.76%N/A -641.25%

In the previous week, Milestone Scientific had 6 more articles in the media than NeurAxis. MarketBeat recorded 8 mentions for Milestone Scientific and 2 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.80 beat Milestone Scientific's score of 0.38 indicating that NeurAxis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Milestone Scientific
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NeurAxis
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Milestone Scientific has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 9.2% of Milestone Scientific shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Milestone Scientific beats NeurAxis on 8 of the 15 factors compared between the two stocks.

How does Milestone Scientific compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Milestone Scientific (NYSE:MLSS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Milestone Scientific has a net margin of -52.01% compared to Hyperfine's net margin of -156.42%. Milestone Scientific's return on equity of -60.26% beat Hyperfine's return on equity.

Company Net Margins Return on Equity Return on Assets
Hyperfine-156.42% -91.18% -55.49%
Milestone Scientific -52.01%-60.26%-40.23%

In the previous week, Milestone Scientific had 6 more articles in the media than Hyperfine. MarketBeat recorded 8 mentions for Milestone Scientific and 2 mentions for Hyperfine. Milestone Scientific's average media sentiment score of 0.38 beat Hyperfine's score of 0.20 indicating that Milestone Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hyperfine
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Milestone Scientific
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Hyperfine has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Milestone Scientific has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Milestone Scientific has lower revenue, but higher earnings than Hyperfine. Milestone Scientific is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hyperfine$11.40M5.23-$35.57M-$0.30N/A
Milestone Scientific$9.42M2.67-$6.93M-$0.04N/A

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 9.2% of Milestone Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hyperfine currently has a consensus target price of $2.03, suggesting a potential upside of 260.58%. Milestone Scientific has a consensus target price of $1.00, suggesting a potential upside of 261.01%. Given Milestone Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Milestone Scientific is more favorable than Hyperfine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperfine
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Milestone Scientific
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Milestone Scientific beats Hyperfine on 9 of the 17 factors compared between the two stocks.

How does Milestone Scientific compare to Microbot Medical?

Milestone Scientific (NYSE:MLSS) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Milestone Scientific has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Milestone Scientific currently has a consensus price target of $1.00, suggesting a potential upside of 261.01%. Microbot Medical has a consensus price target of $5.00, suggesting a potential upside of 625.69%. Given Microbot Medical's higher probable upside, analysts plainly believe Microbot Medical is more favorable than Milestone Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Scientific
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Microbot Medical
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 9.2% of Milestone Scientific shares are held by company insiders. Comparatively, 3.9% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Milestone Scientific and Milestone Scientific both had 8 articles in the media. Milestone Scientific's average media sentiment score of 0.38 beat Microbot Medical's score of 0.18 indicating that Milestone Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Milestone Scientific
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Microbot Medical
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Microbot Medical has a net margin of 0.00% compared to Milestone Scientific's net margin of -52.01%. Microbot Medical's return on equity of -26.20% beat Milestone Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Milestone Scientific-52.01% -60.26% -40.23%
Microbot Medical N/A -26.20%-24.71%

Milestone Scientific has higher revenue and earnings than Microbot Medical. Milestone Scientific is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone Scientific$9.42M2.67-$6.93M-$0.04N/A
Microbot MedicalN/AN/A-$13.14M-$0.26N/A

Summary

Milestone Scientific and Microbot Medical tied by winning 7 of the 14 factors compared between the two stocks.

Get Milestone Scientific News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLSS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLSS vs. The Competition

MetricMilestone ScientificHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$25.11M$5.99B$7.83B$23.06B
Dividend YieldN/A1.68%2.47%3.82%
P/E Ratio-3.9638.0633.9727.33
Price / Sales2.675.398.493.27
Price / CashN/A23.6221.0115.54
Price / Book2.524.174.453.65
Net Income-$6.93M$143.92M$3.52B$1.07B
7 Day Performance-10.56%-5.44%-5.94%-4.20%
1 Month Performance-15.16%-3.64%-4.58%-2.47%
1 Year Performance-9.77%-0.05%-1.95%5.84%

Milestone Scientific Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLSS
Milestone Scientific
1.6166 of 5 stars
$0.28
-5.8%
$1.00
+261.0%
-11.2%$25.11M$9.42MN/A15
KEQU
Kewaunee Scientific
0.9931 of 5 stars
$34.12
+0.0%
N/A-13.9%$98.79M$282M12.361,231
OM
Outset Medical
3.2722 of 5 stars
$4.23
+3.2%
$10.00
+136.4%
-35.8%$79.83M$119.48MN/A310
NRXS
NeurAxis
3.0191 of 5 stars
$6.24
+2.1%
$13.00
+108.3%
+99.6%$78.36M$5.32MN/A24
HYPR
Hyperfine
1.8905 of 5 stars
$0.72
+5.0%
$2.03
+181.4%
-49.9%$76.30M$11.40MN/A102

Related Companies and Tools


This page (NYSE:MLSS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners